Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q3 2014 · 10-Q
Revenue—
Net Income-$1.91M-$1.91MN/M vs Q3 2013 EPS Diluted-$0.01-$0.01N/M vs Q3 2013 Operating Income-$3,141,706N/M Operating Cash Flowderived-$2,601,618—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
ended Sep 30, 2014 · filed Nov 12, 2014 · 43 d after period end